Beta: Sign in
Shares outstandingAs of 2025-12-31 · listed ADS: 112.90B
Shares float: Sign in
Float %: Sign in
Insider ownership: —
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 0.00%
Short ratioDays to cover, as published by FINRA: 1.00
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 52.90%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 51.90%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Profitability

Gross margin: —
Operating marginFY Dec 23: -2103.41%
Net margin: —
EBITDA margin: —
Return on equityNet income (FY Dec 25) ÷ average shareholders equity: -64.72%
Return on assetsNet income (FY Dec 25) ÷ average total assets: -38.74%

Growth

Revenue growth (annual YoY): —
Revenue growth (latest qtr YoY): —
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, FY Dec 25

-0.00

EPS (fwd)

Financial health

Cash & equivalentsas of Dec 25: GBP 8.53M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Dec 25: GBP 61.00K
Debt / equityas of Dec 25: 0.53%
Current ratioas of Dec 25: 2.03
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Dec 25: 2.01
Operating cash flowFY Dec 25: -GBP 5.59M
Free cash flowUnadjusted FCF = CFO − capex · FY Dec 25: -GBP 5.59M
TTM revenue / diluted share: —

BDRX stock Statistics — Biodexa Pharmaceuticals Plc filings, insiders & smart money · Instaport